Mirum Pharmaceuticals, Inc. - common stock (MIRM): Price and Financial Metrics


Mirum Pharmaceuticals, Inc. - common stock (MIRM)

Today's Latest Price: $18.96 USD

0.01 (0.05%)

Updated Sep 25 4:00pm

Add MIRM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MIRM Daily Price Range
MIRM 52-Week Price Range

MIRM Stock Price Chart Technical Analysis Charts


MIRM Price/Volume Stats

Current price $18.96 52-week high $28.31
Prev. close $18.95 52-week low $6.51
Day low $18.64 Volume 36,300
Day high $19.49 Avg. volume 93,661
50-day MA $22.03 Dividend yield N/A
200-day MA $18.33 Market Cap 481.57M

Mirum Pharmaceuticals, Inc. - common stock (MIRM) Company Bio


Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its product candidates include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz on May 7, 2018 and is headquartered in Foster City, CA.


MIRM Latest News Stream


Event/Time News Detail
Loading, please wait...

MIRM Latest Social Stream


Loading social stream, please wait...

View Full MIRM Social Stream

Latest MIRM News From Around the Web

Below are the latest news stories about Mirum Pharmaceuticals Inc that investors may wish to consider to help them evaluate MIRM as an investment opportunity.

Mirum Pharmaceuticals to Present at Investor Conferences in September

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at Investor Conferences in September

Business Wire | September 11, 2020

Mirum Pharmaceuticals (MIRM) Presents At Digital International Liver Congress 2020

The following slide deck was published by Mirum Pharmaceuticals, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 2, 2020

Mirum Pharma launches rolling U.S. maralixibat application for liver disorder-related itchy skin

Ultra-thinly traded small cap Mirum Pharmaceuticals ([[MIRM]] -6.8%) has filed the first part of its rolling U.S. marketing application seeking approval of lead drug maralixibat for the treatment of cholestatic pruritus (itchy skin related to a decrease or arrest of bile flow) in patients with Alagille syndrome, a rare inherited...

Seeking Alpha | September 1, 2020

Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access Program

Mirum initiates rolling NDA submission for maralixibat for the treatment of cholestatic pruritus in patients with ALGS & launches EAP

Yahoo | September 1, 2020

Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients With PFIC2 at Digital International Liver Congress 2020

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Presents Maralixibat Five-Year Transplant-Free Survival Data for Patients with PFIC2 at Digital International Liver Congress

Business Wire | August 29, 2020

Read More 'MIRM' Stories Here

MIRM Price Returns

1-mo -21.13%
3-mo -1.66%
6-mo 35.43%
1-year 95.67%
3-year N/A
5-year N/A
YTD -22.68%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6883 seconds.